Radient Pharmaceuticals Submits Two Abstracts to the American Society of Clinical Oncologists on the Increased Sensitivity of Onko-Sure(R) Combined With CEA for Colorectal Cancer Detection
(firmenpresse) - TUSTIN, CA -- (Marketwire) -- 09/20/11 -- Radient Pharmaceuticals Corporation "the Company" or "Radient" (OTCQX: RXPC) (PINKSHEETS: RXPC), a developer and marketer of In Vitro Diagnostic (IVD) cancer tests, today announced it has submitted two scientific abstracts to the American Society of Clinical Oncologists (ASCO). Both abstracts discussed the results of recent studies on the monitoring and screening of colorectral cancer using Onko-Sure® in conjunction with carcinoembryonic antigen (CEA). When Onko-Sure® was used in conjunction with CEA, the sensitivity was 55% higher compared to that of using CEA alone.
Upon acceptance of these abstracts by ASCO, they will be presented at ASCO's 2012 Gastrointestinal Cancers Symposium in San Francisco.
"Radient continues to conduct research that is yielding very positive results for Onko-Sure® as a diagnostic and monitoring tool for colorectal cancer along with many other types of cancers. We look forward to sharing our results with the medical community through presentations at scientific conferences," stated Radient Chairman and CEO Douglas MacLellan.
Onko-Sure® is cleared for market by the US FDA for the treatment and recurrence monitoring of colorectal cancer. Onko-Sure® is a blood test that runs on an ELISA platform and is available through certified clinical reference labs.
For additional information on Radient Pharmaceuticals Corporation and its products visit: or e-mail . For Investor Relations contact Dilek Mir at: or 714-881-0244.
The following table is intended to provide the latest information on Radient's business metrics:
Headquartered in Tustin, California, Radient Pharmaceuticals Corporation is dedicated to saving lives and money for patients and global healthcare systems through the deployment of its FDA-cleared In Vitro Diagnostic Onko-Sure® cancer test kit for colorectal cancer treatment and recurrence monitoring. The Company's focus is on the discovery, development and commercialization of unique high-value diagnostic tests that will help physicians answer important clinical questions related to early disease state detection, treatment strategy, and the monitoring of disease progression or recurrence. To learn more about our company, products, and potentially life-saving cancer test, visit .
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: The statements contained in this document include certain predictions and projections that may be considered forward-looking statements under securities law. These statements involve a number of important risks and uncertainties that could cause actual results to differ materially including, but not limited to, the performance of joint venture partners, as well as other economic, competitive and technological factors involving the Company's operations, markets, services, products, and prices. With respect to Radient Pharmaceuticals Corporation, except for the historical information contained herein, the matters discussed in this document are forward-looking statements involving risks and uncertainties that could cause actual results to differ materially from those in such forward-looking statements.
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 20.09.2011 - 05:00 Uhr
Sprache: Deutsch
News-ID 1038871
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
TUSTIN, CA
Phone:
Kategorie:
Hospitals, Facilities and Providers
Anmerkungen:
Diese Pressemitteilung wurde bisher 158 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Radient Pharmaceuticals Submits Two Abstracts to the American Society of Clinical Oncologists on the Increased Sensitivity of Onko-Sure(R) Combined With CEA for Colorectal Cancer Detection
"
steht unter der journalistisch-redaktionellen Verantwortung von
Radient Pharmaceuticals Corporation (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
